Advertisement

Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens

  • Matthew C. Hernandez
  • John R. Bergquist
  • Jennifer L. Leiting
  • Tommy Ivanics
  • Lin Yang
  • Rory L. Smoot
  • David M. Nagorney
  • Mark J. TrutyEmail author
Original Article

Abstract

Background

Patient-derived xenografts (PDX) are clinically relevant human cancer models that can be used to guide individualized medicine. We aimed to generate PDX models from clinically obtained biopsy specimens (surgical or image-guided) hypothesizing that low volume biopsy specimens could provide sufficient viable tissue to successfully engraft PDX models from patients with unresectable or metastatic disease.

Materials and Methods

We maintain a prospective high volume gastrointestinal malignancy PDX program. With informed consent and institutional approval, biopsy specimens (surgical or image-guided) were obtained from patients with unresectable or metastatic tumors: pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, gastric and gallbladder carcinoma. Biopsies were implanted into immunodeficient mice. Tumor growth was monitored, viable tumor was passed into subsequent generations, and histopathology was confirmed.

Results

In this study, biopsy specimens from 29 patients were used for PDX engraftment. Successful PDX engraftment was variable with highest engraftment rates in gastric and gallbladder carcinoma specimens (100%) compared to engraftment rates of 33% and 29% in PDAC and cholangiocarcinoma respectively. PDX models created from metastasis biopsies compared to unresectable primary tumor tissue demonstrated higher engraftment rates (69% versus 15.4%, p = 0.001). PDX models demonstrated higher engraftment rates when biopsies were obtained during surgical operations (n = 15) compared to image-guided (n = 14) (73% versus 14%, p = 0.003). Patient age, pretreatment status, or ischemic time was not different between biopsy methods.

Conclusions

PDX models can be successfully created from clinical biopsy specimens in patients with metastatic or unresectable GI cancers. The use of clinical biopsy specimens for PDX engraftment can expand the repertoire of stage-specific PDX models for downstream basic/translational research.

Keywords

PDX Biopsy, patient derived xenograft Unresectable FNA 

Notes

Author Contribution

Study design was developed by MCH, LY, JRB, and MJT. Data generation was performed by MCH, TI, LY, MJT, MLK, RLS, SPC, and DMN. Data analysis and interpretation were performed by MCH, LY, JLL, JRB, and MJT. Manuscript writing was performed by MCH, TI, LY, MJT, JRB, JLL, MLK, RLS, SPC, and DMN.

Funding

The authors acknowledge funding from Roger Thrun and the Mayo Clinic Clinician Investigator program.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Tentler JJ, Tan AC, Weekes CD, et al. Development 2014;9(6):338–350. doi: https://doi.org/10.1038/nrclinonc.2012.61.Patient-derived. Google Scholar
  2. 2.
    Delitto D, Pham K, Vlada AC, et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol 2015;185(5):1297–1303. doi: https://doi.org/10.1016/j.ajpath.2015.01.016.CrossRefGoogle Scholar
  3. 3.
    Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84(10):1424–1431. doi: https://doi.org/10.1054/bjoc.2001.1796.CrossRefGoogle Scholar
  4. 4.
    Daniel VC, Marchionni L, Hierman JS, et al. NIH Public Access. 2010;69(8). doi: https://doi.org/10.1158/0008-5472.CAN-08-4210.A.
  5. 5.
    Gandara DR, Lara PN, Mack PC. Patient-derived xenografts for investigation of acquired resistance in oncogene-driven cancers: Building a better mousetrap. J Clin Oncol 2015;33(26):2839–2840. doi: https://doi.org/10.1200/JCO.2015.61.9692.CrossRefGoogle Scholar
  6. 6.
    Chang Q, Foltz WD, Chaudary N, Hill RP, Hedley DW. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. Int J Cancer 2013;133(1):225–234. doi: https://doi.org/10.1002/ijc.28006.CrossRefGoogle Scholar
  7. 7.
    Francis OL, Milford TAM, Beldiman C, Payne KJ. Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia. J Investig Med 2016;64(3):740–744. doi: https://doi.org/10.1136/jim-2016-000076.CrossRefGoogle Scholar
  8. 8.
    Puig I, Chicote I, Tenbaum SP, et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res 2013;19(24):6787–6801. doi: https://doi.org/10.1158/1078-0432.CCR-12-1740.CrossRefGoogle Scholar
  9. 9.
    Murphy SJ, Hart SN, Lima JF, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013;145(5):1098–1109. doi: https://doi.org/10.1053/j.gastro.2013.07.049.CrossRefGoogle Scholar
  10. 10.
    Roife D, Kang Y, Wang L, et al. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 2017;161(5):1246–1254. doi: https://doi.org/10.1016/j.surg.2016.11.020.CrossRefGoogle Scholar
  11. 11.
    Allaway RJ, Fischer DA, Abreu FB de, et al. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget 2016;7(13):17087–17102. doi: https://doi.org/10.18632/oncotarget.7718.CrossRefGoogle Scholar
  12. 12.
    Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res 2014;74(11):2913–2921. doi: https://doi.org/10.1158/0008-5472.CAN-14-0155.CrossRefGoogle Scholar
  13. 13.
    Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7(7):2076–2084. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11448926. Accessed 1 Oct 2017.Google Scholar
  14. 14.
    Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing internationalJ Hepatol trends in mortality rates for liver, biliary and pancreatic tumours. 2002;37(6):806–813. doi: https://doi.org/10.1016/S0168-8278(02)00297-0.
  15. 15.
    Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: Update and future perspectives. Dig Liver Dis 2010;42(4):253–260. doi: https://doi.org/10.1016/j.dld.2009.12.008.CrossRefGoogle Scholar
  16. 16.
    Gillen S, Schuster T, Büschenfelde CM Zum, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7(4):1–15. doi: https://doi.org/10.1371/journal.pmed.1000267.CrossRefGoogle Scholar
  17. 17.
    Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 2016;21(5):594–599. doi: https://doi.org/10.1634/theoncologist.2015-0446.CrossRefGoogle Scholar
  18. 18.
    Amin MB, Edge SB, Greene FL, et al, eds. AJCC cancer staging manual. 8th edn. New York: Springer; 2017.Google Scholar
  19. 19.
    Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol (Madr) 2016;55(9–10):1158–1160. doi: https://doi.org/10.1080/0284186X.2016.1197419.CrossRefGoogle Scholar
  20. 20.
    Hidalgo M, Amant F, Biankin a. V., et al. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov 2014:998–1013. doi: https://doi.org/10.1158/2159-8290.CD-14-0001.
  21. 21.
    Lee LS, Andersen DK, Ashida R, et al. Endoscopic Ultrasound and Related Technologies for the Diagnosis and Treatment of Pancreatic Disease - Research Gaps and Opportunities. Pancreas 2017;46(10):1. doi: https://doi.org/10.1097/MPA.0000000000000936. CrossRefGoogle Scholar
  22. 22.
    Chen J, Jiang K, Wu J, et al. Application of intraoperative transluminal core-biopsy for diagnosis of pancreatic head mass: A single center 15-year experience. Pancreatology 2017:1–5. doi: https://doi.org/10.1016/j.pan.2017.09.001.
  23. 23.
    Golan T, Stossel C, Schvimer M, et al. Pancreatic cancer ascites xenograft – an expeditious model mirroring advanced therapeutic resistant disease. Oncotarget. 2017;8(25):40778–40790.CrossRefGoogle Scholar
  24. 24.
    Nakajima T, Geddie W, Anayama T, et al. Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Lung Cancer 2015;89(2):110–114. doi: https://doi.org/10.1016/j.lungcan.2015.05.018.CrossRefGoogle Scholar
  25. 25.
    Allaway RJ, Fischer DA, de Abreu FB, et al. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget 2016;7(13):17087–17102. doi: https://doi.org/10.18632/oncotarget.7718.CrossRefGoogle Scholar
  26. 26.
    Berry W, Algar E, Kumar B, et al. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Int J Cancer 2017;140(10):2331–2343. doi: https://doi.org/10.1002/ijc.30648.CrossRefGoogle Scholar
  27. 27.
    Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 2011;40(5):644–652. doi: https://doi.org/10.1097/MPA.0b013e31821ff741.CrossRefGoogle Scholar
  28. 28.
    Yu J, Qin B, Moyer AM, et al. Establishing and characterizing patient-derived xenografts using prechemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res. 2017;19(1):130.CrossRefGoogle Scholar
  29. 29.
    Boj SF, Hwang C Il, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015;160(1–2):324–338. doi: https://doi.org/10.1016/j.cell.2014.12.021.CrossRefGoogle Scholar
  30. 30.
    Kim E, Kim YJ, Kim K, Song C, Kim JS, Oh DY, Nam EM CE. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery. Br J Radol. 2017;90(1080):20170308.CrossRefGoogle Scholar
  31. 31.
    Seidensticker R, Seidensticker M, Doegen K, et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2016;2016:8732521.CrossRefGoogle Scholar
  32. 32.
    Brandi G, Venturi M, Pantaleo MA, et al. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016;48(3):231–241. doi: https://doi.org/10.1016/j.dld.2015.11.017.CrossRefGoogle Scholar
  33. 33.
    Zhuang YP, Zhu YP, Wang HY, et al. Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy. Braz J Med Biol Res 2017;50(6):1–7. doi: https://doi.org/10.1590/1414-431X20176000.CrossRefGoogle Scholar
  34. 34.
    Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet 2017;49(11):1567–1575. doi: https://doi.org/10.1038/ng.3967.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  1. 1.Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of SurgeryMayo ClinicRochesterUSA
  2. 2.Department of SurgeryHenry Ford Medical CenterDetroitUSA
  3. 3.Center for Individualized MedicineMayo ClinicRochesterUSA

Personalised recommendations